Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy

Inclusion Criteria: * Patients must give their written informed consent before any procedure related to the study is performed. * Patients with renal clear cell carcinoma metastatic or locally advanced, histologically or cytologically documented.The patients with metastasic disease must be not condidated to curative nefrectomy as investigator criteria. * Assessable or measurable disease according to RECIST criteria. The lesions previosly radiated is not considered as target. * Ages equal or superior to 18 years old. * ECOG ≤ 1 * Patients with a life expectancy superior to 12 weeks. * Patients with adequate organic function, according to the following criteria: 1. . Medular reserve: Neutrophils absolute count≥ 1.5 x 10\^9/L Platelets ≥ 100 x 10\^9/L Haemoglobin ≥ 9g/dl 2. . Hepatic function: Total bilirubin \< 1.5 times the superior limit of normality ALT and AST \< 2.5 times the superior limit of normality (\< 5 times the superior limit of normality in case of liver failure due to cancer) 3. . Seric Albumin ≥ 1.5 times the superior limit of normality 4. . Renal Function: Cleary creatinine \> 30ml/min 5. . FEVI \> LIN according to ECO or MUGA * Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions while on study Exclusion Criteria: * Pregnant or breastfeeding women. Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication. Both men and women included in the study must use an adequate contraceptive method. * Patients that have received sistemic treatment previous to metastasic disease. * Previous nefrectomy. * Mayor Surgery, radiotherapy or sistemic therapy received in the last 3 weeks previous to the inclusion of the patient in the study, except paliative radiotherapy upper no target lesions. * Radiotherapy upper \> 25% bone marrow. * Patients that are participating in any clinical trial. * Patients with a primary cancer diagnosis in thast 3 years, except superficial basaliomas, superficial escamous carcinoma or in situ cervix carcinoma with aducuate treatment. * Following events in the last 12 months previous to begin the treatment: myocardial infarction, unstable o severe angina, coronary/periferic place of arterial by-pass, congestive cardiac insufficiency, brain-vascular accident included transitory ischemia or lung embolism. * Arterial uncontrolled hypertension nor controlated with drugs ( \>150/100 mmHg despite adequate medical treatment). * Cardiac arrhythmia with grade NCI CTCAE ≥2, auricular fibrillation all grade and/or QTc interval\> 450mseg in men and \> 470 mseg in women. * Actually treatment with therapeutic dose with acenocumarol (except low dose for deep venous thrombosis). * Patients that present previously known positive serology for HIV. * Abuse of substances, clinical conditions, psychological or social, that may interfere with the patient's participation in the study or with the evaluation of the study's results.